Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5980965 | 0.86 | ESR1 (0.71) | ESR1ESR2XDH | |
| SCHEMBL27627364 | 0.85 | ESR1 (0.48) | ESR1ESR2CYP11B1CYP11B2PDGFRB | |
| SCHEMBL3014632 | 0.80 | PGR (0.52) | ESR1ESR2CYP11B1CYP11B2HSD17B1 | |
| SCHEMBL4485744 | 0.80 | ESR1 (0.55) | ESR1ESR2CYP11B1CYP11B2PDGFRB | |
| SCHEMBL13527431 | 0.78 | ESR1 (0.50) | ESR1ESR2XDH | |
| SCHEMBL28469839 | 0.78 | ERN1 (0.60) | ESR1ESR2HSD17B1HSD17B2PDGFRB | |
| SCHEMBL13527430 | 0.77 | ESR1 (0.44) | ESR1ESR2CYP11B1CYP11B2XDH | |
| SCHEMBL5981371 | 0.74 | ESR1 (0.76) | ESR1ESR2PDGFRBPDGFRAXDH | |
| SCHEMBL5980999 | 0.74 | ESR2 (0.76) | ESR1ESR2PGRAR | |
| SCHEMBL19722074 | 0.73 | CYP17A1 (0.57) | ESR2CYP11B1CYP11B2PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557237-B2 | Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile | WYETH (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557237-B2 | Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile | WYETH (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557237-B2 | Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile | WYETH (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1663929-A2 | PROCESS FOR THE SYNTHESIS OF 3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXYNAPHTHONITRILE | Wyeth (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026105-A2 | PROCESS FOR THE SYNTHESIS OF 3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXYNAPHTHONITRILE | WYETH (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054870-A1 | Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile | WYETH (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054870-A1 | Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile | HRH4, HRH1, HRH3 | ESR1 2818/4885ESR2 1795/4885CYP11B1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.